Falk G. Bechara

St. Josef Hospital
Bochum, NW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 222 publications

Development of a predictive marker panel for the individualised bDMARD therapy of psoriatic arthritis: protocol for a prospective observational study (Integrate-PsA).

Development of a predictive marker panel for the individualised bDMARD therapy of psoriatic arthritis: protocol for a prospective observational study (Integrate-PsA).

Journal: BMJ open

Published: July 16, 2026

Title Not Found

Title Not Found

Journal: Dermatologie (Heidelberg, Germany)

Published: June 30, 2026

Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.

Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials.

Journal: Nature medicine

Published: May 28, 2026

Medical and Surgical Management of Hidradenitis Suppurativa.

Medical and Surgical Management of Hidradenitis Suppurativa.

Journal: Journal of clinical medicine

Published: May 22, 2026

Criteria for Hidradenitis Suppurativa Competence Centers.

Criteria for Hidradenitis Suppurativa Competence Centers.

Journal: Dermatology and therapy

Published: March 20, 2026

Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase 2 Randomized Clinical Trial.

Lutikizumab in Adults With Moderate to Severe Hidradenitis Suppurativa After Anti-TNF Therapy Failure: A Phase 2 Randomized Clinical Trial.

Journal: JAMA dermatology

Published: March 18, 2026

Body composition of hidradenitis suppurativa compared to psoriasis and healthy controls.

Body composition of hidradenitis suppurativa compared to psoriasis and healthy controls.

Journal: Clinical and experimental dermatology

Published: March 14, 2026

Dietary patterns, metabolic pathways and metainflammation in hidradenitis suppurativa: a systematic review.

Dietary patterns, metabolic pathways and metainflammation in hidradenitis suppurativa: a systematic review.

Journal: Frontiers in immunology

Published: March 14, 2026

Response to Kvist-Hansen et al, "Baseline monocytes ≥925/μL appear to represent a rare outlier phenotype rather than a generalizable predictor of adalimumab response in hidradenitis suppurativa".

Response to Kvist-Hansen et al, "Baseline monocytes ≥925/μL appear to represent a rare outlier phenotype rather than a generalizable predictor of adalimumab response in hidradenitis suppurativa".

Journal: Journal of the American Academy of Dermatology

Published: February 21, 2026

Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa: A Consensus Exercise Using a Modified Delphi Approach.

Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa: A Consensus Exercise Using a Modified Delphi Approach.

Journal: JAMA dermatology

Published: November 26, 2025

Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study.

Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: November 14, 2025

A practical approach for management of hidradenitis suppurativa in primary care

A practical approach for management of hidradenitis suppurativa in primary care

Journal: MMW Fortschritte der Medizin

Published: October 23, 2025

Showing 1-12 of 222

Last Updated: 09/26/2026